Deerfield Beach, FL / Sept 19, 2014 / The Federal Reserve?s monetary policy meeting was the talking point at the start of this week. All eyes were on Fed?s monetary policy statement, which was released on Wednesday. The Fed surprised the market by maintaining its dovish stance and saying there is considerable time before an interest rate hike.

The Fed?s statement calmed investors and also gave a boost to stocks, which rose in trading on Thursday. Since the Fed meeting, the focus has once again shifted to equity markets and Alibaba?s (NYSE: BABA) much-awaited IPO. The Chinese e-commerce company completed its IPO on Thursday, pricing it at $68 per share. The offering is the largest ever in the U.S.

Alibaba has been assigned a value of $167.62 billion, which makes it one of the most valuable technology companies in the world. Alibaba shares begin trading on the NYSE on Friday and not surprisingly the technology stock is creating a lot of buzz. Here are some stocks that investors are likely to focus on Friday.

Oracle Corporation (NYSE: ORCL)

Another technology company that is in news today is Oracle after Larry Ellison stepped down from the CEO position. The news has hurt shares of the Redwood City, California-based company?s shares in early trading. At last check, the stock was down 3.27% to $40.19.

Oracle announced late on Thursday that Larry Ellison will step down from the position of CEO and will serve as Executive Chairman of the Board and Chief Technology Officer. Safra Catz and Mark Hurd have been promoted to the role of CEO. Ellison stepped down as CEO after leading Oracle for more than three decades.

Ellison said on Thursday that Catz and Hurd will now report to the Oracle Board rather than him. Ellison further said that all the other reporting relationships will remain unchanged.

Concur Technologies Inc. (NASDAQ: CNQR)

Another technology stock creating buzz today is Concur Technologies, a provider of integrated travel and expense management solutions for companies of all industries, sizes and geographies. The Bellevue, Washington-based company provides cloud computing software solutions on a subscription basis.

Concur shares have surged more than 18% in early trading on Friday after the company entered into an agreement with SAP?s U.S. subsidiary SAP America Inc. under which SAP will acquire Concur. Under the terms of the agreement, SAP will acquire Concur for $129 per share, which represents a premium of 20% over the September 17 closing price.

Steve Singh, CEO of Concur, said that Concur has always been focused on making solutions for real customer problems and with SAP, the company has a great opportunity to advance that mission.

IsoRay Inc. (NYSEMKT: ISR)

In the small cap world, one stock that has been creating buzz lately is IsoRay Inc. (NYSEMKT: ISR). The Richland, Washington-based company is an emerging player in the brachytherapy treatment market. Brachytherapy is an internal radiation therapy for treatment of prostate and other forms of cancer.

IsoRay has been generating excitement in the medical community lately as its Cesium-131 isotope produced excellent results in treating metastatic brain cancer. The company announced the publication of the first major peer reviewed study, which showed superior results using its Cesium-131 seeds in the treatment of metastatic brain cancer.

Commenting on the development, Dwight Babcock, CEO of IsoRay, last month said that the company is extremely excited to have growing evidence that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body and specifically now metastatic brain cancer. Babcock believes that the company?s marketing efforts will be enhanced by teaming up with medical industry thought leaders as they seek better solutions and outcomes for their patients.

Given the solid progress IsoRay has been making in creating awareness of its Cesium-131, it is not surprising that the company?s shares have surged more than 330% so far this year.

Contact

Emerging Equities Report
954.360.9998
info@wwfinancial.com

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Equities is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Equities may be compensated for its services in the form of cash-based compensation in the companies it writes about.

Source: Emerging Equities Report